Indian court rejects patent linkage in Bayer's sorafenib case - update
This article was originally published in Scrip
Executive Summary
The Delhi High Court has indicted Bayer for attempting to use "speculative" litigation in India, in a case concerning Cipla's application to introduce a generic version of Bayer's anticancer Nexavar (sorafenib tosylate).